Literature DB >> 24854491

Preoperative prognostic neurologic index for glioblastoma patients receiving tumor resection.

Hsiang-Kuang Liang1, Chun-Wei Wang, Han-Min Tseng, Chao-Yuan Huang, Keng-Hsueh Lan, Yu-Hsuan Chen, San-Lin You, Jason Chia-Hsien Cheng, Ann-Lii Cheng, Sung-Hsin Kuo.   

Abstract

BACKGROUND: Neurologic status is one of the major prognostic factors in glioblastoma patients; however, no consensus exists on a clinical index for predicting patient outcomes. The purpose of this study was to evaluate the correlation between neurologic deficits and clinical outcomes in glioblastoma patients, and to develop a prognostic neurologic index for identifying patients with poor outcomes.
METHODS: Patients receiving tumor resection with pathologically confirmed glioblastoma were retrospectively evaluated. The patients' preoperative neurologic deficits were categorized, and patients with poor overall survival (OS) were identified. Other common prognostic factors, including age, performance, imaging findings, and extent of resection, were analyzed.
RESULTS: We evaluated 162 glioblastoma patients receiving tumor resection between February 2000 and December 2011, of whom 54 received adjuvant radiotherapy (RT) alone and 84 received concurrent chemo-RT with temozolomide. At a median follow-up of 57.6 (range 26.3-88.9) months, 26 patients had survived without loss to follow-up. We defined adverse neurologic status by using an index of combined increased intracranial pressure (IICP) and non-IICP signs. In univariate analysis, the median OS of patients with and without adverse neurologic status were 9.6 and 18.7 months, respectively (p < 0.001). In multivariate analyses, adverse neurologic status remained significantly associated with poor OS (hazard ratio 2.18, 95 % confidence interval 1.54-3.10).
CONCLUSIONS: Our proposed neurologic index enables significantly identifying glioblastoma patients receiving tumor resection with poor outcomes, independent of other common prognostic factors. Using the index provides a preoperative predictor of prognosis in glioblastoma patients receiving tumor resection.

Entities:  

Mesh:

Year:  2014        PMID: 24854491     DOI: 10.1245/s10434-014-3793-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.

Authors:  Erkan Topkan; Ugur Selek; Yurday Ozdemir; Berna A Yildirim; Ozan C Guler; Fuat Ciner; Huseyin Mertsoylu; Kadir Tufan
Journal:  J Neurooncol       Date:  2018-04-25       Impact factor: 4.130

2.  Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide.

Authors:  Erkan Topkan; Ali A Besen; Huseyin Mertsoylu; Ahmet Kucuk; Berrin Pehlivan; Ugur Selek
Journal:  Int J Inflam       Date:  2020-06-08

3.  The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients.

Authors:  Johannes Kasper; Tim Wende; Michael Karl Fehrenbach; Florian Wilhelmy; Katja Jähne; Clara Frydrychowicz; Gordian Prasse; Jürgen Meixensberger; Felix Arlt
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.